A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

By sjmartinez • February 15, 2023

Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). Arthritis Rheumatol. 2023 Feb 14. doi: 10.1002/art.42477. Epub ahead of print. PMID: 36787101.

Tags: Publications, Rheumatology

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]

Unflavored electronic cigarette exposure induces alterations in airway ciliary structure and function

Durra A, Cherry C, Luo C, Hou E, Frauenpreis A, Purkayastha A, Passamano I, Makanani S, Castillo K, Lund A, Choi W, Sen C, Chandran[...]

Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement

Jones BLH, López L, Garg M. Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement. BMC Med Educ. 2025[...]